Zosano Pharma, Inc. is a biopharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications.
Zosano (formely known as The Macroflux Company) was as an internal venture within Alza (J&J), a pioneer in the field of drug delivery systems. In 2006, the internal venture became an independent company. Zosano is funded by New Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments, all well-recognized leaders in the venture capital healthcare arena. Zosano aims to develop products independently and is also actively pursuing strategic licensing and co-development arrangements. Zosano is a fully integrated development company, including a recently launched cGMP manufacturing capability. Our management team has extensive experience leading research, development, and operational activities within successful pharmaceuticals and much of our core staff come from Alza (J&J) where they worked for over 8 years to perfect this unique technology. Zosano’s patent portfolio is both deep and broad with more than 19 patent families in the US, 12 in the EU, and 20 patent applications pending.
Zosano is advancing a pipeline of drug candidates based on the ZP Patch Technology – a proprietary transdermal delivery technology capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin’s outer layer and ensuring significant and rapid therapeutic effect. This proven technology offers several key benefits, including efficacy and safety comparable to approved injectables, needle-free delivery, a self-administered patch, rapid onset of action and room temperature storage. Zosano’s transdermal delivery technology has been clinically tested in over 400 patients with five different peptides and a vaccine.
Our lead clinical program, the ZP-PTH rapid delivery patch for the treatment of severe osteoporosis, is being developed as an improved alternative to daily injections and is preparing to enter a phase 3 pivotal trial.